Feedback / Questions
Xospata (gilteritinib) - Astellas
Vanflyta (quizartinib) - Daiichi Sankyo
Nexavar (sorafenib) - Bayer, Amgen
Rydapt (midostaurin) - Novartis
crenolanib besylate (ARO-002) - AROG
https://www.onclive.com/view/developing-resistance-with-flt3-inhibitors-in-aml
Apr 28, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next